Saturday 17 October 2026
Export ACGN’s income statement to Excel — free account
Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
| Mar '23 | Dec '22 | Sep '22 | Jun '22 | Older periods | |
|---|---|---|---|---|---|
| (169.66%) | (113.18%) | (43.59%) | (49.57%) |
+8 more TTM periods Free account |
|
| (75.58%) | (34.36%) | (16.41%) | (41.25%) | ||
ROIC |
(135.35%) | (64.66%) | (62.09%) | 0.00% | |
Return on Tangible Assets |
335.83% | 657.47% | (108.03%) | (69.90%) | |
Average Days of Receivables |
91.58 | 239.65 | 411.75 | — | |
Free Cash Flow per Share |
(4.00) | (7.52) | (4.90) | (5.41) | |
Free Cash Flow |
(29.78) | (24.49) | (15.34) | (16.84) | |
| Other line items | |||||
Cash ROIC |
(120.73%) | (48.05%) | (19.99%) | (36.92%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.74 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.11 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 154,235.31 | 2,843.16 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
175.36% | 190.17% | 463.18% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
167.82% | 190.56% | 536.59% | 0.00% | |
Share Based Compensation of Revenue |
32.73% | 34.14% | 118.61% | 0.00% | |
Interest Coverage |
— | — | (203.50) | (4,909.00) | |
Operating CF/Net income |
0.73 | 1.05 | 1.31 | 1.15 | |
Depreciation/Fixed assets |
2,771.25 | 2.14 | 1.45 | 1.36 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.18 | 1.97 | 0.56 | 0.00 | |
Operating CF per Share |
(4.00) | (7.52) | (4.90) | (5.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates